Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2024-03-28 Orexo Orexo publishes the Annual and Sustainability Report for 2023 Rapporter Ladda ner | Visa Stäng
2024-03-28 Orexo Orexo publicerar års- och hållbarhetsredovisning för 2023 Rapporter Ladda ner | Visa Stäng
2024-03-21 Penser Access by Carnegie Penser Access by Carnegie: Orexo - Stärka finanser Pressreleaser Visa Stäng
2024-03-15 Orexo Correction: Notice of Annual General Meeting of Orexo Pressreleaser Visa Stäng
2024-03-15 Orexo Rättelse: Kallelse till årsstämma i Orexo Pressreleaser Visa Stäng
2024-03-15 Orexo Notice of Annual General Meeting of Orexo Pressreleaser Ladda ner | Visa Stäng
2024-03-15 Orexo Kallelse till årsstämma i Orexo Pressreleaser Ladda ner | Visa Stäng
2024-03-13 Orexo Orexo har framgångsrikt emitterat seniora säkerställda sociala obligationer med rörlig ränta om SEK 500 m och offentliggör resultatet av återköpserbjudandet avseende sina befintliga obligationer Pressreleaser Ladda ner | Visa Stäng
2024-03-13 Orexo Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds Pressreleaser Ladda ner | Visa Stäng
2024-03-08 Orexo Orexo överväger emission av seniora säkerställda sociala obligationer med rörlig ränta och offentliggör villkorat återköpserbjudande avseende sina befintliga obligationer Pressreleaser Ladda ner | Visa Stäng
2024-03-08 Orexo Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds Pressreleaser Ladda ner | Visa Stäng
2024-03-08 Orexo Orexo stärker sitt hållbarhetsarbete genom att etablera ett socialt finansieringsramverk Pressreleaser Ladda ner | Visa Stäng
2024-03-08 Orexo Orexo strengthens its sustainability work by establishing a social financing framework Pressreleaser Ladda ner | Visa Stäng
2024-02-12 Orexo Orexo and Sobi agree to advance feasibility study with AmorphOX Pressreleaser Ladda ner | Visa Stäng
2024-02-12 Orexo Orexo och Sobi avancerar förstudie med AmorphOX Pressreleaser Ladda ner | Visa Stäng
2024-02-08 Orexo Orexo Interim Report Q4 2023, incl. Full Year Report Rapporter Ladda ner | Visa Stäng
2024-02-08 Orexo Orexo delårsrapport kv 4 2023, inkl. bokslutskommuniké Rapporter Ladda ner | Visa Stäng
2024-02-06 Orexo Orexos studieresultat för OX640 presenteras vid AAAAI:s Annual Meeting 2024 i Washington, DC, USA Pressreleaser Ladda ner | Visa Stäng
2024-02-06 Orexo Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC Pressreleaser Ladda ner | Visa Stäng
2024-02-01 Penser Access by Carnegie Penser Access by Carnegie: Orexo - Motvind från valutan Pressreleaser Visa Stäng
2023-11-29 Penser Access Penser Access: Interview with Orexo - Erik Penser Bank - Nov 29th 2023 Pressreleaser Visa Stäng
2023-11-28 Orexo Orexo meddelar att FDA accepterat registreringsansökan för granskning av OX124, ett högdosläkemedel vid opioidöverdos Pressreleaser Ladda ner | Visa Stäng
2023-11-28 Orexo Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose Pressreleaser Ladda ner | Visa Stäng
2023-11-06 Penser Access Penser Access: Intervju med Orexo - Erik Penser Bank - 6 november 2023 Pressreleaser Visa Stäng
2023-11-03 Penser Access Penser Access: Går mot lönsamhet, men tillväxten dröjer - Orexo Pressreleaser Visa Stäng
2023-11-02 Orexo Orexo Q3 2023 Interim Report Rapporter Ladda ner | Visa Stäng
2023-11-02 Orexo Orexo delårsrapport kv 3 2023 Rapporter Ladda ner | Visa Stäng
2023-10-27 Orexo Orexo meddelar förändringar i styrelsen Pressreleaser Ladda ner | Visa Stäng
2023-10-27 Orexo Orexo announces changes in the company's Board of Directors Pressreleaser Ladda ner | Visa Stäng
2023-10-26 Orexo Orexo:s valberedning inför årsstämman 2024 Pressreleaser Ladda ner | Visa Stäng
2023-10-26 Orexo Orexo's Nomination Committee for the Annual General Meeting 2024 Pressreleaser Ladda ner | Visa Stäng
2023-10-26 Orexo Report from Orexo's extraordinary general meeting Pressreleaser Ladda ner | Visa Stäng
2023-10-26 Orexo Kommuniké från Orexo:s extra bolagsstämma Pressreleaser Ladda ner | Visa Stäng
2023-10-11 Orexo Orexo offentliggör data från MODIA-studien som utvärderar effekten på användning av otillåtna opioider Pressreleaser Ladda ner | Visa Stäng
2023-10-11 Orexo Orexo announces data from the MODIA® study evaluating impact on use of illicit opioids Pressreleaser Ladda ner | Visa Stäng
2023-10-02 Orexo Notice of Extraordinary General Meeting in Orexo AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-10-02 Orexo Kallelse till extra bolagsstämma i Orexo AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-10-02 Penser Access Penser Access: Intervju med Orexo - Erik Penser Bank - 2 oktober 2023 Pressreleaser Visa Stäng
2023-09-27 Orexo BioStock Investor Meeting: Orexo Pressreleaser Visa Stäng
2023-09-27 Orexo BioStock Investor Meeting: Orexo Pressreleaser Visa Stäng
2023-09-18 Orexo Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose Pressreleaser Ladda ner | Visa Stäng
2023-09-18 Orexo Orexo lämnar in registreringsansökan till FDA för OX124, ett högdos-läkemedel vid opioidöverdos Pressreleaser Ladda ner | Visa Stäng
2023-09-05 Orexo Orexo to participate in Pareto Securities' 14[th] Annual Healthcare Conference 2023 Pressreleaser Ladda ner | Visa Stäng
2023-09-05 Orexo Orexo deltar i Pareto Securities 14[th] Annual Healthcare Conference 2023 Pressreleaser Ladda ner | Visa Stäng
2023-08-29 Orexo Orexo secures patent protection in the US for OX640, a nasal epinephrine powder product Pressreleaser Ladda ner | Visa Stäng
2023-08-29 Orexo Orexo säkrar patentskydd i USA för OX640, ett pulverbaserat nasalt adrenalinläkemedel Pressreleaser Ladda ner | Visa Stäng
2023-07-24 Orexo Orexo's patent win for ZUBSOLV[®] appealed Pressreleaser Ladda ner | Visa Stäng
2023-07-24 Orexo Orexo:s seger i patenttvisten för ZUBSOLV[®] överklagas Pressreleaser Ladda ner | Visa Stäng
2023-07-20 Penser Access Penser Access: Det har vänt, men värderingen släpar - Orexo Pressreleaser Visa Stäng
2023-07-19 Penser Access Penser Access: Intervju med Orexo - Erik Penser Bank - 19 juli 2023 Pressreleaser Visa Stäng
2023-07-18 Orexo Orexo delårsrapport kv 2 2023 Rapporter Ladda ner | Visa Stäng
2023-07-18 Orexo Orexo Q2 2023 Interim Report Rapporter Ladda ner | Visa Stäng
2023-07-03 Penser Access Penser Access: Intervju med Orexo - Erik Penser Bank - 3 juli 2023 Pressreleaser Visa Stäng
2023-07-03 Penser Access Penser Access: Segrar i patenttvist - Orexo Pressreleaser Visa Stäng
2023-07-01 Orexo Orexo wins patent litigation for ZUBSOLV® in the US Pressreleaser Ladda ner | Visa Stäng
2023-07-01 Orexo Orexo vinner patenttvist för ZUBSOLV® i USA Pressreleaser Ladda ner | Visa Stäng
2023-05-22 Penser Access Penser Access: Krisvärdering inför viktiga besked - Orexo Pressreleaser Visa Stäng
2023-05-03 Penser Access Penser Access: Intervju med Orexo - Erik Penser Bank - 2 maj 2023 Pressreleaser Visa Stäng
2023-04-27 Orexo Orexo Interim Report Q1 2023 Rapporter Ladda ner | Visa Stäng
2023-04-27 Orexo Orexo delårsrapport kv 1 2023 Rapporter Ladda ner | Visa Stäng
2023-04-18 Orexo Report from Orexo AB's annual general meeting Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 18 Apr 2023 | Orexo

Report from Orexo AB’s annual general meeting

Uppsala, April 18, 2023

Election of the board of directors and auditor

The annual general meeting in Orexo AB (publ) on 18 April 2023 resolved, in accordance with the nomination committee’s proposal, that the number of board members shall be eight with no deputy board members. James Noble, Staffan Lindstrand, Henrik Kjær Hansen, Fred Wilkinson, Mary Pat Christie, Charlotte Hansson, Christine Rankin and Michael J Matly were re-elected as ordinary board members. James Noble was elected as chairman of the board. Ernst & Young Aktiebolag was re-elected as auditor.

Fees to the board of directors and the auditor

The annual general meeting also resolved on fees to the board of directors in accordance with the nomination committee’s proposal. The fees to the board of directors shall amount to SEK 3,550,000 to be allocated as follows: SEK 900,000 to the chairman and SEK 300,000 to each of the other board members, and in total SEK 400,000 to be allocated to the members of the audit committee so that the chairman of the committee receives SEK 200,000 and SEK 200,000 are allocated in equal parts between the other members of the committee, and in total 150,000 to be allocated to the members of the remuneration committee in equal parts between the members of the committee, and that fees to the auditor shall be paid against approved accounts.

Further, the annual general meeting resolved on an additional board fee in accordance with the nomination committee’s proposal to the independent board members James Noble, Staffan Lindstrand, Fred Wilkinson, Mary Pat Christie, Charlotte Hansson, Christine Rankin and Michael J Matly of SEK 1,050,000, subject to (i) the board member’s acquisition of shares in Orexo for the entire part (after taxes) of such additional board fee as soon as possible following the annual general meeting’s resolution and the pay-out of the additional board fee, and (ii) the board member’s commitment not to sell the shares during the board member’s entire tenure on the Orexo board. The additional board fee is to be allocated as follows: SEK 450,000 to the chairman and SEK 100,000 to each of the other independent board members.

Nomination committee

The annual general meeting resolved to adopt procedures for the appointment of the nomination committee for the annual general meeting 2024 substantially in accordance with the same procedure as the preceding year.

Approval of income statement and balance sheets, appropriation of the company’s profit or loss and discharge from liability

The annual general meeting approved the income statement and the balance sheet for the parent company, as well as the consolidated income statement and the consolidated balance sheet for the financial year 2022. It was resolved, in accordance with the board of directors’ proposal, that there shall be no dividend for 2022 and that the results of the company shall be carried forward. The meeting also discharged the members of the board and the managing director from liability for the financial year 2022.

Authorization to issue new shares

The annual general meeting resolved to authorize the board of directors to resolve to issue new shares on one or several occasions until the next annual general meeting, with or without preferential rights for the shareholders, against cash payment or against payment through set-off or in kind, or otherwise on special conditions. However, such issue of shares must never result in the company’s issued share capital or the number of shares in the company at any time, being increased by more than a total of 20 per cent. The purpose of the authorization is to enable the board to make corporate acquisitions, product acquisitions or to enter into collaboration agreements, or to raise working capital or broaden the shareholder base.

Authorization to repurchase and transfer shares

The annual general meeting resolved to authorize the board of directors to resolve to repurchase, on one or several occasions until the next annual general meeting, as many own shares as may be purchased without the company’s holding at any time exceeding 10 per cent of the total number of shares in the company. Further, it was resolved to authorize the board of directors to resolve, on one or several occasions until the next annual general meeting, to transfer (sell) own shares.

The purpose of the authorization to repurchase own shares is to promote efficient capital usage in the company, to provide flexibility as regards the company’s possibilities to distribute capital to its shareholders and for use in the context of the company’s incentive plans. The purpose of the authorization to transfer own shares is to enable the board to make corporate acquisitions, product acquisitions or enter into collaboration agreements, or to raise working capital or broaden the shareholder base or for use in the context of the company’s incentive plans.

Long-term incentive program LTIP 2023

The annual general meeting resolved, in accordance with the board’s proposal, to adopt a new long-term incentive program for not more than 130 selected employees within the Orexo group, LTIP 2023. LTIP 2023 substantially corresponds with LTIP 2022, a performance based long-term incentive program adopted at the annual general meeting 2022.

Long-term incentive program LTIP Stay-on 2023

The annual general meeting resolved, in accordance with the board’s proposal, to adopt a new long-term incentive program for approximately 13 Global Management Team employees and US Leadership Team employees within the Orexo group, LTIP Stay-on 2023. LTIP Stay-on 2023 substantially corresponds with LTIP Stay-on 2022, a performance based long-term incentive program adopted at the annual general meeting 2022.

Complete proposals regarding the resolutions by the annual general meeting in accordance with the above together with the presentation from the managing director’s speech are available at Orexo’s website, www.orexo.com.

The Board

For further information please contact:
Orexo AB (publ.)

Lena Wange, IR & Communications Director
Tel: +46 (0)18780 88 00
E-mail: ir@orexo.com

About Orexo

Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2022 amounted to SEK 624 million and the number of employees was 126. Orexo is listed on the Nasdaq Stockholm Main Market (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

For more information about Orexo please visit www.orexo.com. You can also follow Orexin on Twitter, @orexoabpubl,LinkedIn, and YouTube.

The information was sent for publication, through the agency of the contact person set out above, on April 18, 2023, at 7.30 pm CET.

2023-04-18 Orexo Kommuniké från Orexo AB:s årsstämma Pressreleaser Ladda ner | Visa Stäng
2023-04-04 Penser Access Penser Access: Intervju med Orexo - Erik Penser Bank - 3 april 2023 Pressreleaser Visa Stäng
2023-04-03 Orexo Orexo shares new timeline for the high-dose rescue medication for opioid overdose, OX124 Pressreleaser Ladda ner | Visa Stäng
2023-04-03 Orexo Orexo uppdaterar tidplanen för högdosläkemedlet vid opioidöverdos, OX124 Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

26 Apr 2024 | Årsstämma 2023
29 Apr 2024 | Årligutdelning
8 May 2024 | Kvartalsrapport 2024-Q1
17 Jul 2024 | Kvartalsrapport 2024-Q2
14 Nov 2024 | Kvartalsrapport 2024-Q3
6 Feb 2025 | Bokslutskommuniké 2024